Role of IL-5 in asthma and airway remodelling

IF 6.3 2区医学 Q1 ALLERGY Clinical and Experimental Allergy Pub Date : 2024-06-27 DOI:10.1111/cea.14489

Rola AbuJabal, Rakhee K. Ramakrishnan, Khuloud Bajbouj, Qutayba Hamid

{"title":"Role of IL-5 in asthma and airway remodelling","authors":"Rola AbuJabal, Rakhee K. Ramakrishnan, Khuloud Bajbouj, Qutayba Hamid","doi":"10.1111/cea.14489","DOIUrl":null,"url":null,"abstract":"<p>Asthma is a common and burdensome chronic inflammatory airway disease that affects both children and adults. One of the main concerns with asthma is the manifestation of irreversible tissue remodelling of the airways due to the chronic inflammatory environment that eventually disrupts the whole structure of the airways. Most people with troublesome asthma are treated with inhaled corticosteroids. However, the development of steroid resistance is a commonly encountered issue, necessitating other treatment options for these patients. Biological therapies are a promising therapeutic approach for people with steroid-resistant asthma. Interleukin 5 is recently gaining a lot of attention as a biological target relevant to the tissue remodelling process. Since IL-5-neutralizing monoclonal antibodies (mepolizumab, reslizumab and benralizumab) are currently available for clinical use, this review aims to revisit the role of IL-5 in asthma pathogenesis at large and airway remodelling in particular, in addition to exploring its role as a target for biological treatments.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 8","pages":"538-549"},"PeriodicalIF":6.3000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14489","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cea.14489","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Asthma is a common and burdensome chronic inflammatory airway disease that affects both children and adults. One of the main concerns with asthma is the manifestation of irreversible tissue remodelling of the airways due to the chronic inflammatory environment that eventually disrupts the whole structure of the airways. Most people with troublesome asthma are treated with inhaled corticosteroids. However, the development of steroid resistance is a commonly encountered issue, necessitating other treatment options for these patients. Biological therapies are a promising therapeutic approach for people with steroid-resistant asthma. Interleukin 5 is recently gaining a lot of attention as a biological target relevant to the tissue remodelling process. Since IL-5-neutralizing monoclonal antibodies (mepolizumab, reslizumab and benralizumab) are currently available for clinical use, this review aims to revisit the role of IL-5 in asthma pathogenesis at large and airway remodelling in particular, in addition to exploring its role as a target for biological treatments.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

IL-5 在哮喘和气道重塑中的作用

哮喘是一种常见且负担沉重的慢性气道炎症性疾病，对儿童和成年人都有影响。哮喘的主要问题之一是由于慢性炎症环境导致气道出现不可逆的组织重塑，最终破坏气道的整体结构。大多数哮喘患者都会接受吸入皮质类固醇治疗。然而，类固醇耐药性的产生是一个普遍遇到的问题，因此有必要为这些患者提供其他治疗方案。对于类固醇耐药性哮喘患者来说，生物疗法是一种很有前景的治疗方法。最近，白细胞介素 5 作为与组织重塑过程相关的生物靶点受到广泛关注。由于 IL-5 中和单克隆抗体（mepolizumab、reslizumab 和 benralizumab）目前已可用于临床，本综述旨在重新审视 IL-5 在整个哮喘发病机制，尤其是气道重塑过程中的作用，并探讨其作为生物疗法靶点的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Allergy 医学-过敏

CiteScore

10.40

自引率

9.80%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field. In response to the increasing number of quality submissions, since 1996 the journals size has increased by over 30%. Clinical & Experimental Allergy is essential reading for allergy practitioners and research scientists with an interest in allergic diseases and mechanisms. Truly international in appeal, Clinical & Experimental Allergy publishes clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.